CTOs on the Move

Sano Informed Prescribing

www.thinksano.com

 
Sano Informed Prescribing, Inc. is creating game-changing personal and population health management capabilities, previously unattainable in the healthcare market, by revolutionizing medication therapy through the fast, clinically precise detection of medications in patients. The vision of Sano Informed Prescribing is to improve individual and population health; enable healthcare professionals to evaluate, adjust and implement best possible medication therapy programs; and reduce the costs associated with quality healthcare. Sano Informed Prescribing’s mission is to ensure that every patient receives the most effective drug therapy possible. We will do this by providing precise, patient-specific medication analyses that empower healthcare professionals to tailor care; achieve ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.thinksano.com
  • 393 Nichol Mill Lane Suite 34
    Franklin, TN USA 37067
  • Phone: 615.933.0900

Executives

Name Title Contact Details

Similar Companies

AA Medical

AA Medical Store improves healthcare around the world by supplying refurbished state-of the-art surgical devices at the best price, with the best warranty, and unmatched service and support.

Advent Pharmaceuticals

Advent Pharmaceuticals is a East Windsor, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccuMed

AccuMed Inc. is a Lawrence Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.